<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00125775</url>
  </required_header>
  <id_info>
    <org_study_id>CRE-2005.134</org_study_id>
    <nct_id>NCT00125775</nct_id>
  </id_info>
  <brief_title>Does Extra-High Dose Hepatitis B Vaccination Confer Longer Serological Protection in Peritoneal Dialysis Patients?</brief_title>
  <official_title>Phase 4 Study of Recombinant Hepatitis B Vaccine in Peritoneal Dialysis Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis B virus causes inflammation of the liver which is detrimental to the end-stage&#xD;
      renal disease patients on dialysis. Hepatitis B vaccine is recommended for this high-risk&#xD;
      population although the vaccine protection remains suboptimal and does not last long.&#xD;
&#xD;
      The purpose of this study is to determine the best vaccination strategy over a 6-month period&#xD;
      using recombinant hepatitis B vaccine (Engerix-B) in peritoneal dialysis patients. Current&#xD;
      data show that the traditional Engerix-B vaccine dose (40 micrograms) does not always lead to&#xD;
      protective and long-lasting hepatitis B surface antibody. The investigators, therefore,&#xD;
      decided to compare the usual 40-micrograms with an 80-microgram dose strategy of vaccine&#xD;
      protection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the present randomized study is to evaluate the optimum strategy of&#xD;
      recombinant hepatitis B vaccination in the maintenance of protective anti-HBs antibody among&#xD;
      end-stage renal disease patients on peritoneal dialysis. This study is designed to establish&#xD;
      whether a three-dose schedule of 80 microgram Engerix-B vaccine could maintain protective&#xD;
      antibody response among dialysis patients. The secondary aim is to identify the effects of&#xD;
      dosing on various subgroups of dialysis patients.&#xD;
&#xD;
      Viral hepatitis B infection remains a major health hazard for end-stage renal disease&#xD;
      patients on dialysis. The direct costs of hepatitis B infection and long term impact on&#xD;
      morbidity and renal transplantation are substantial. Apart from the devastating consequences&#xD;
      of hepatitis B infection on patients on dialysis or after transplantation, infected patients&#xD;
      are potential reservoirs for infecting other patients and haemodialysis staff. Antibody&#xD;
      production achieved in renal patients is suboptimal; the most effective method of vaccination&#xD;
      to prevent hepatitis B infections in end-stage renal disease subjects has hitherto been&#xD;
      unanswered by the current literature and the latest Cochrane Collaboration review.&#xD;
&#xD;
      Given the relatively low seroconversion rate and maintenance of protective hepatitis antibody&#xD;
      levels among end-stage renal disease patients, a treatment strategy using various doses of&#xD;
      recombinant hepatitis B vaccine (Engerix-B) has been recently explored. In an observational&#xD;
      study, the investigators demonstrated no statistically significant difference in response&#xD;
      rate between patients receiving three recommended doses of Engerix-B intramuscularly (40&#xD;
      micrograms each dose) and those with four times the normal adult dose (80 micrograms each&#xD;
      dose), (78% versus 100%, P = 0.23). On the other hand, according to the Kaplan-Meier&#xD;
      estimates, 78 percent of patients in the 40 micrograms Engerix-B vaccination group and 96&#xD;
      percent of patients in the 80 micrograms dosing group had maintained the seroprotective&#xD;
      levels of antibody to hepatitis B surface antigen (anti-HBs) at 12 months after initial&#xD;
      response. This difference corresponds to an absolute risk reduction of 18 percent for losing&#xD;
      the antibody response with a three-dose schedule of 80 micrograms Engerix-B vaccination&#xD;
      program. In other words, the investigators estimate that giving Engerix-B 80 micrograms dose&#xD;
      would lead to one extra end-stage renal disease subject with persistent seroprotective&#xD;
      anti-HBs level at one year for every 5.6 patients treated (number needed to treat to benefit&#xD;
      NNT, 5.6; 95% confidence interval, 5.4 to 5.8).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hepatitis B surface antibody anti-HBs level â‰¥ 10 IU/L 3 months after completion of the third dose and the persistence of protective anti-HBs 12 months after completion of the third dose of Engerix-B vaccine</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Peritoneal Dialysis</condition>
  <condition>Renal Disease, End-Stage</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Engerix-B 40 mcg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Engerix-B 80 mcg dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Engerix-B</intervention_name>
    <description>Engerix-B at 0, 1, 6 months</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age above 18 years&#xD;
&#xD;
          -  End-stage renal disease and on maintenance peritoneal dialysis&#xD;
&#xD;
          -  Serologically negative for hepatitis B surface antigen (HBsAg) and antibody to&#xD;
             hepatitis core antigen (anti-HBc)&#xD;
&#xD;
          -  No history of receiving hepatitis B vaccination&#xD;
&#xD;
          -  Willingness to give written informed consent and willingness to participate in and&#xD;
             comply with the study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Expected survival less than 6 months&#xD;
&#xD;
          -  Those who refused vaccination&#xD;
&#xD;
          -  Active malignancy&#xD;
&#xD;
          -  Alcoholic liver disease&#xD;
&#xD;
          -  Chronic hepatitis C and/or human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Receiving immunosuppressive medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai Ming Chow, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prince of Wales Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>New Territories</city>
        <zip>SAR</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>August 1, 2005</study_first_submitted>
  <study_first_submitted_qc>August 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2005</study_first_posted>
  <last_update_submitted>January 6, 2010</last_update_submitted>
  <last_update_submitted_qc>January 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Kai Ming CHOW</name_title>
    <organization>Chinese University of Hong Kong</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

